Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock?

Hims & Hers falls -10.3%

Truist Raises Price Target on Hims & Hers Health to $27 From $23, Keeps Hold Rating

Hims & Hers Health Inc : Truist Securities Raises Target Price to $27 from $23

Moderately bullish activity in Hims and Hers Health with shares up 3.39%

Hims & Hers Health is Maintained at Neutral by Citigroup

FDA Advisers Back First Four of Seven Unapproved Peptides Under Review for Looser Rules

Hims Gains After FDA Panel Votes to Place Popularly Used Peptide Bpc-157 on Compounding List

Hims & Hers Health Shares up 10% After FDA Advisory Panel Votes to Place Bpc-157 Peptide on Allowed Pharmacy Compounding List

Hims & Hers Shares up 2% After Telehealth Firm Urged FDA to Broaden Access to Some Peptides in Panel Meeting

Peptides Could Soon Become Widely Available in the U.S. Here's What Happens Next.

Hims & Hers Health Inc : Citigroup Raises Target Price to $35 from $28

Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares Valued at $229,075.99

Trump's FDA May Soon Back Peptides. Should You Buy In?

Hims & Hers Accounting Chief Exits

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 9.35%

Press Release: Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Hims & Hers Sets Second-quarter Results Release and Investor Call